

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

July 13, 2022

Brendan Smith Chief Financial Officer CRISPR Therapeutics AG Baarerstrasse 14 6300 Zug Switzerland

Re: CRISPR Therapeutics AG
Form 10-K for the fiscal year ended December 31, 2021
Filed February 15, 2022
File No. 001-37923

Dear Mr. Smith:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance Office of Life Sciences